Sun Pharmaceutical Industries reported a 27 per cent year-on-year increase in consolidated net profit to 2,894.7 crore for Q1FY27, with revenue growing 10 per cent to 15,299.8 crore, driven by strong performance in India and innovative medicines.
Mahindra Group Chairman Anand Mahindra announced the company would adopt an 'attack mode' strategy, accelerating investment, innovation, and execution to capitalise on opportunities arising from prolonged geopolitical and economic uncertainty.
Larsen & Toubro (L&T) is investing Rs 5,000 crore over five years to enter the automotive components sector, focusing on electric vehicle (EV) motors, safety systems, and connected-vehicle technologies, aiming to become a Tier-I auto supplier.
Jaguar Land Rover (JLR) India reported its highest-ever first-quarter retail sales for FY27, with 1,665 vehicles retailed, an 11 per cent year-on-year increase, largely due to sustained demand for premium SUVs and the benefits of the India-UK Free Trade Agreement.
India's passenger vehicle industry is poised for a record-breaking year in 2026, propelled by robust dispatches in the first half of the calendar year and strong demand for utility vehicles, despite facing several economic challenges.
Manipal Health Enterprises is set to launch India's largest healthcare initial public offering (IPO) on July 29, aiming to raise Rs 9,275.22 crore to fund expansion and debt reduction, with the issue closing on July 31.
Dr Reddy's Laboratories reported a 68.7 per cent year-on-year decline in consolidated net profit to Rs 443.5 crore in Q1 FY27, primarily due to the end of its lenalidomide sales agreement, a Rs 240-crore provision for semaglutide API inventory quality issues, and elevated freight costs.
TVS Motor Company reported a significant 56.8 per cent year-on-year increase in net profit to 1,036 crore in Q1FY27, driven by record sales volumes, an improved product mix, and robust demand in both domestic and international markets, with management anticipating continued double-digit industry growth.
The vaccine has been cleared for use in individuals aged 4 to 60 years and can be administered irrespective of whether the taker has had dengue before, eliminating the need for pre-vaccination screening.
BMW Group India says every Re 1 depreciation in the rupee against the euro trims its profit margin by about 1 per cent, prompting the company to consider further price increases.
Nissan Motor India aims to achieve a fourfold increase in domestic sales, targeting 100,000 units annually, and export another 100,000 vehicles from its Chennai plant by financial year 2027-28 (FY28), marking a significant revival of its presence in the Indian passenger vehicle market.
Tata Motors is set to acquire Italy's Iveco Group, a strategic move aimed at propelling the Indian automaker into the top four global commercial vehicle (CV) manufacturers, with projected annual revenues of $35 billion-$40 billion within five years.
Companies are investing heavily in complex injectables, respiratory therapies and biosimilars to improve margins and diversify portfolios.
Health experts warn that rising temperatures could create a growing burden of silent and cumulative health stress across the population.
The luxury carmaker plans to drive growth through local assembly of the MINI Countryman, expansion into 10 new cities and a broader product portfolio.
Sun Pharmaceutical Industries reported strong consolidated numbers for Q4 FY26, with net profit rising 26 per cent year-on-year to 2,714 crore, despite continued weakness in its US generics business. Growth in innovative medicines and increased R&D investments are helping to offset these pressures.
Escalating geopolitical tensions in West Asia are beginning to disrupt India's automotive supply chain, leading to rising commodity prices, logistics bottlenecks, material shortages, and pressure on consumer demand, with two-wheeler makers already raising prices.
Biocon is actively seeking in-licensing opportunities to expand its biosimilars portfolio, focusing on products that complement existing therapy areas, as the company shifts to a 'consolidate' phase with a strong emphasis on improving capacity utilisation, expanding margins, and driving return on capital employed.
Piramal Pharma anticipates a significant turnaround in financial year 2026-27 (FY27), projecting early-to-mid teens revenue expansion and a sharp improvement in profitability, driven by improved business momentum, new product acquisitions, and structural tailwinds.
India's electric motorcycle market is experiencing significant growth, with a 28 per cent year-on-year increase in volumes, as new product launches and improved total cost of ownership attract a broader base of riders beyond early adopters.
